Correlation between the presence of antibodies to the Epstein-barr virus nuclear antigen type 2 and antibodies to the rheumatoid arthritis nuclear antigen in patients with rheumatoid arthritis

Authors

  • Thomas B. Sculley PhD,

    Corresponding author
    1. Queensland Institute of Medical Research and the Department of Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia
    • Queensland Institute of Medical Research, Bramston Terrace, Herston, Brisbane, Australia 4006
    Search for more papers by this author
  • John H. Pope PhD,

    1. Queensland Institute of Medical Research and the Department of Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia
    Search for more papers by this author
  • Ron A. Hazelton MB, BS

    1. Queensland Institute of Medical Research and the Department of Medicine, Princess Alexandra Hospital, University of Queensland, Brisbane, Australia
    Search for more papers by this author

Abstract

The incidence of antibodies to Epstein-Barr nuclear antigen type 2 (EBNA-2) was determined in sera from rheumatoid arthritis (RA) patients and control subjects, by protein immunoblotting. Sixty-eight percent of the RA patients and 48% of the controls possessed anti-EBNA-2 antibodies. The titer of anti-rheumatoid arthritis nuclear antigen (RANA) in RA patient sera showed a stronger correlation with serum reactions to EBNA-2 than with reactions to EBNA-1. Our results indicate that the presence of EBNA-2 may make a major contribution to the RANA reaction.

Ancillary